• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

综合非核心领域的相关信息,以支持多标准决策分析(MCDA)进行决策。

Synthesis of relevant information around non-core domains to support Multi-Criteria Decision Analysis (MCDA) for decision making.

作者信息

Bayón-Yusta Juan Carlos, Gutiérrez-Iglesias Asun, Galnares-Cordero Lorea, Gutiérrez-Ibarluzea Iñaki

机构信息

Basque Foundation for Health Innovation and Research (BIOEF), Barakaldo, Spain.

Osteba, Basque Office for HTA, Barakaldo, Spain.

出版信息

GMS Health Innov Technol. 2024 Mar 27;18:Doc02. doi: 10.3205/hta000139. eCollection 2024.

DOI:10.3205/hta000139
PMID:38655192
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11035910/
Abstract

Countries fundamentally base macro and micro decision making in the field of health on economic considerations, the budgetary impact of technologies being a major criterion. Nevertheless, the value of the technology of interest and its dimensions are more complex if we seek to take decisions based on the value itself. The use of structured and explicit approaches that require the assessment of multiple criteria that reflect the dimensions of this value may significantly improve the quality of the decision making. Multi-criteria decision analysis (MCDA) is a complementary decision-making tool that is able to systematically incorporate dimensions or domains such as ethical, organisational, legal, environmental and social considerations, as well as costs and benefits of medical interventions, together with the distinct perspectives of the interested parties. The objective of this article is to propose the implementation of analysis of non-core domains, in reports of Health Technology Assessment (HTA) agencies/units. To assess the scientific evidence on MCDA techniques a systematic review was conducted using structured searches in biomedical databases and websites of various HTA organisations. A consensus group was held using the nominal group technique and involving users of healthcare services, providers, managers and academics. Complementary, a survey was sent to HTA agencies to ascertain the degree of implementation of MCDA in their methods. 42 articles reporting the use of non-core criteria for the assessment of health technologies were included in the analysis. From these articles, a total of 216 non-core criteria were retrieved and categorised into domains by the researchers, and of these, 56 were classified as socioeconomic, 59 as organisational, 10 as legal, 8 as environmental and 47 as ethical, while 36 were considered to relate to other domains. The consensus group, based on the 216 non-core criteria obtained from the systematic review, proposed, and defined 26 criteria that participants considered necessary for decision making in healthcare. The consensus group did not consider that any of the domains should be given more weight than others or that any individual criteria should dominate. These approaches can serve as a framework of reference for a well-structured systematic discussion concerning the basis of individual criteria and the evidence supporting them.

摘要

各国在卫生领域的宏观和微观决策基本上都基于经济考量,技术的预算影响是一个主要标准。然而,如果我们试图基于技术价值本身做出决策,那么相关技术的价值及其维度会更加复杂。使用结构化且明确的方法,要求对反映该价值维度的多个标准进行评估,可能会显著提高决策质量。多标准决策分析(MCDA)是一种辅助决策工具,能够系统地纳入伦理、组织、法律、环境和社会考量等维度或领域,以及医疗干预的成本和收益,同时兼顾相关各方的不同观点。本文的目的是在卫生技术评估(HTA)机构/单位的报告中提议实施非核心领域分析。为评估MCDA技术的科学证据,我们在生物医学数据库和各HTA组织的网站上进行结构化检索,开展了一项系统综述。使用名义群体技术召开了一次共识小组会议,参与者包括医疗服务使用者、提供者、管理者和学者。此外,还向HTA机构发送了一份调查问卷,以确定MCDA在其方法中的实施程度。分析纳入了42篇报告使用非核心标准评估卫生技术的文章。研究人员从这些文章中总共检索到216条非核心标准,并将其分类到不同领域,其中56条归类为社会经济领域,59条为组织领域,10条为法律领域,8条为环境领域,47条为伦理领域,另有36条被认为与其他领域相关。基于系统综述得出的216条非核心标准,共识小组提出并定义了26条参与者认为医疗保健决策所需的标准。共识小组认为,没有任何一个领域应比其他领域更具权重,也没有任何单个标准应占据主导地位。这些方法可作为一个参考框架,用于就各个标准的依据及其支持证据进行结构良好的系统讨论。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/b7ef3063ad65/HINT-18-02-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/06f646d5aa1c/HINT-18-02-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/0d9f8ea988f4/HINT-18-02-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/63964c63b85a/HINT-18-02-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/73dad02f6090/HINT-18-02-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/dd3f36de2667/HINT-18-02-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/4802e6fc7d48/HINT-18-02-t-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/b7ef3063ad65/HINT-18-02-g-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/06f646d5aa1c/HINT-18-02-t-001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/0d9f8ea988f4/HINT-18-02-t-002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/63964c63b85a/HINT-18-02-t-003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/73dad02f6090/HINT-18-02-t-004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/dd3f36de2667/HINT-18-02-t-005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/4802e6fc7d48/HINT-18-02-t-006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/45f6/11035910/b7ef3063ad65/HINT-18-02-g-001.jpg

相似文献

1
Synthesis of relevant information around non-core domains to support Multi-Criteria Decision Analysis (MCDA) for decision making.综合非核心领域的相关信息,以支持多标准决策分析(MCDA)进行决策。
GMS Health Innov Technol. 2024 Mar 27;18:Doc02. doi: 10.3205/hta000139. eCollection 2024.
2
Multicriteria decision analysis (MCDA) for health technology assessment: the Queensland Health experience.用于卫生技术评估的多标准决策分析(MCDA):昆士兰卫生部门的经验
Aust Health Rev. 2019 Oct;43(5):591-599. doi: 10.1071/AH18042.
3
Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.在流行地区,服用抗叶酸抗疟药物的人群中,叶酸补充剂与疟疾易感性和严重程度的关系。
Cochrane Database Syst Rev. 2022 Feb 1;2(2022):CD014217. doi: 10.1002/14651858.CD014217.
4
Bridging health technology assessment (HTA) and efficient health care decision making with multicriteria decision analysis (MCDA): applying the EVIDEM framework to medicines appraisal.将健康技术评估(HTA)与多准则决策分析(MCDA)相结合,以实现高效的医疗保健决策:将 EVIDEM 框架应用于药品评估。
Med Decis Making. 2012 Mar-Apr;32(2):376-88. doi: 10.1177/0272989X11416870. Epub 2011 Oct 10.
5
Bridging health technology assessment (HTA) with multicriteria decision analyses (MCDA): field testing of the EVIDEM framework for coverage decisions by a public payer in Canada.将卫生技术评估 (HTA) 与多准则决策分析 (MCDA) 相结合:在加拿大,对公共支付方进行覆盖决策的 EVIDEM 框架进行现场测试。
BMC Health Serv Res. 2011 Nov 30;11:329. doi: 10.1186/1472-6963-11-329.
6
Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).平衡医学创新不同阶段的成本与效益:多标准决策分析(MCDA)的系统评价
BMC Health Serv Res. 2015 Jul 9;15:262. doi: 10.1186/s12913-015-0930-0.
7
The future of Cochrane Neonatal.考克兰新生儿协作网的未来。
Early Hum Dev. 2020 Nov;150:105191. doi: 10.1016/j.earlhumdev.2020.105191. Epub 2020 Sep 12.
8
Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa.南非宫颈癌筛查检测覆盖的多准则决策分析(MCDA)框架的现场测试。
Cost Eff Resour Alloc. 2012 Feb 29;10(1):2. doi: 10.1186/1478-7547-10-2.
9
Multicriteria Decision Analysis to Support Health Technology Assessment Agencies: Benefits, Limitations, and the Way Forward.多准则决策分析支持卫生技术评估机构:收益、限制和未来发展方向。
Value Health. 2019 Nov;22(11):1283-1288. doi: 10.1016/j.jval.2019.06.014. Epub 2019 Oct 16.
10
Multi-Criteria Decision Analysis (MCDA) Models in Health Technology Assessment of Orphan Drugs-a Systematic Literature Review. Next Steps in Methodology Development?罕见病药物卫生技术评估中的多标准决策分析(MCDA)模型——系统文献综述。方法学发展的下一步?
Front Public Health. 2018 Oct 15;6:287. doi: 10.3389/fpubh.2018.00287. eCollection 2018.

本文引用的文献

1
Integrating Empirical Analysis and Normative Inquiry in Health Technology Assessment: The Values in Doing Assessments of Health Technologies Approach.将实证分析与规范探究整合于卫生技术评估:卫生技术评估方法中的评估价值观
Int J Technol Assess Health Care. 2022 Jun 23;38(1):e52. doi: 10.1017/S0266462321001768.
2
The Use of MCDA in HTA: Great Potential, but More Effort Needed.多准则决策分析在卫生技术评估中的应用:潜力巨大,但仍需努力。
Value Health. 2018 Apr;21(4):394-397. doi: 10.1016/j.jval.2017.10.001. Epub 2017 Nov 22.
3
Multiple Criteria Decision Analysis in Health Technology Assessment for Drugs: Just Another Illusion?
药物卫生技术评估中的多标准决策分析:只是另一种幻想?
Appl Health Econ Health Policy. 2018 Feb;16(1):1-4. doi: 10.1007/s40258-017-0345-7.
4
Appraising the holistic value of Lenvatinib for radio-iodine refractory differentiated thyroid cancer: A multi-country study applying pragmatic MCDA.评估乐伐替尼对放射性碘难治性分化型甲状腺癌的整体价值:一项应用实用多标准决策分析的多国研究
BMC Cancer. 2017 Apr 17;17(1):272. doi: 10.1186/s12885-017-3258-9.
5
Using Multicriteria Approaches to Assess the Value of Health Care.运用多标准方法评估医疗保健的价值。
Value Health. 2017 Feb;20(2):251-255. doi: 10.1016/j.jval.2016.11.011.
6
Discrepancies between multicriteria decision analysis-based ranking and intuitive ranking for pharmaceutical benefit-risk profiles in a hypothetical setting.在一个假设情境中,基于多标准决策分析的药物效益-风险概况排名与直观排名之间的差异。
J Clin Pharm Ther. 2017 Feb;42(1):80-86. doi: 10.1111/jcpt.12486. Epub 2016 Dec 2.
7
Multiple Criteria Decision Analysis for Health Care Decision Making--Emerging Good Practices: Report 2 of the ISPOR MCDA Emerging Good Practices Task Force.用于医疗保健决策的多标准决策分析——新兴良好实践:ISPOR多标准决策分析新兴良好实践工作组报告2
Value Health. 2016 Mar-Apr;19(2):125-37. doi: 10.1016/j.jval.2015.12.016. Epub 2016 Mar 7.
8
Challenges in Using MCDA for Reimbursement Decisions on New Medicines?在使用多标准决策分析(MCDA)进行新药报销决策时面临的挑战?
Value Health. 2016 Mar-Apr;19(2):123-4. doi: 10.1016/j.jval.2016.02.001. Epub 2016 Mar 10.
9
Multiple Criteria Decision Analysis for Health Care Decision Making--An Introduction: Report 1 of the ISPOR MCDA Emerging Good Practices Task Force.用于医疗保健决策的多标准决策分析——简介:ISPOR多标准决策分析新兴良好实践工作组报告1
Value Health. 2016 Jan;19(1):1-13. doi: 10.1016/j.jval.2015.12.003. Epub 2016 Jan 8.
10
Can the EVIDEM Framework Tackle Issues Raised by Evaluating Treatments for Rare Diseases: Analysis of Issues and Policies, and Context-Specific Adaptation.EVIDEM框架能否解决评估罕见病治疗方法所引发的问题:问题与政策分析以及因地制宜的调整
Pharmacoeconomics. 2016 Mar;34(3):285-301. doi: 10.1007/s40273-015-0340-5.